Home
About
Our Mission
Leadership
Board of Directors
Scientific Advisory Board
Science
Our Approach
The B Cell Advantage
Research
Pipeline
Investors & Media
Press Releases
News Articles
Publications & Presentations
Contact
Careers
Home
About
Our Mission
Leadership
Board of Directors
Scientific Advisory Board
Science
Our Approach
The B Cell Advantage
Research
Pipeline
Investors & Media
Press Releases
News Articles
Publications & Presentations
Contact
Careers
News
All
Press Releases
News Articles
Publications & Presentations
February 07, 2025
Safety and Initial Activity of Autologous Human B Cells Genetically Engineered to Express Human Iduronidase Using the Sleeping Beauty Transposon System: Results from a First-in-Human Clinical Trial in Subjects with MPS I
Results from a First-in-Human Clinical Trial in Subjects with MPS I
Related
News Articles
Citeline | February 27, 2025
Immusoft Goes For Cell Therapy Plan ‘B’
Read More
Press Releases
PR Newswire | January 27, 2025
Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium™ 2025
Read More
